Applied Filters
CMA fines drugmakers £260m for 10,000% price hike
The UK’s Competition and Markets Authority has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.
UK Supreme Court shoots down NHS £220m drug patent suit
The UK Government has failed to convince UK Supreme Court judges that Servier Laboratories misrepresented its blood pressure drugs patent in legal proceedings to block generic competitors from entering the market.
English High Court strikes out bad faith ‘Revolax’ TM
A Warrington-based distributor of aesthetic and cosmetic products has lost its UK trademark for a dermal filler brand after the English High Court found it to have registered the brand in bad faith.
EU backs compulsory licensing for COVID vaccines
The European Union has submitted a new proposal to the World Trade Organisation, which backs compulsory licensing agreements for COVID-19 vaccines when negotiations fail.
Bardehle opens Paris life sciences practice with two hires
Munich-based firm Bardehle Pagenberg has established a life sciences practice at its Paris office with two recent hires.
UC Berkeley loses CRISPR patent at EPO
The University of California Berkeley has lost a CRISPR patent in Europe in the latest twist in the long-running IP saga over the gene-editing technology.
Sanofi and C4X in $493m licensing deal
UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Lundbeck loses €150m pay-for-delay appeal
Lundbeck has lost an appeal to the Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.
UK implored to back COVID-19 IP waiver at WTO
The UK has been urged to back a proposed IP waiver related to COVID-19 treatments before the World Trade Organisation by business leaders, academics, economists and trade unions.
Five minutes with… Penny Gilbert
The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.
